This document outlines key preventative measures to minimize complications associated with inflammatory bowel disease (IBD) treatment, emphasizing the importance of infection screening and vaccination protocols. Combination therapies carry a higher risk of infection than anti-TNF monotherapy, particularly for tuberculosis reactivation and viral infections linked to thiopurines. Screening for infections such as hepatitis B and C, HIV, and latent tuberculosis is essential before initiating biological or immunomodulatory therapies. Vaccination against preventable diseases should be completed before starting immunosuppressive treatments, with careful timing for live vaccines. The document also addresses cancer risk management, noting no significant increase in cancer incidence associated with anti-TNF agents, vedolizumab, or ustekinumab, although higher risks are linked to Janus kinase inhibitors.